{"entity":{"id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","aka":[],"tldr":"A phase 2 trial of Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.","summary":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder is a phase 2 interventional study registered as NCT07475806 by Astellas Pharma Global Development, Inc., with 240 participants planned, started 2026-03-12 and due to reach its primary completion in 2027-11-30. Interventions recorded: Enfortumab Vedotin and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07475806","url":"https://clinicaltrials.gov/study/NCT07475806"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["enfortumab-vedotin","pembrolizumab"],"companies":["astellas","pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07475806","phase":"2","setting":"An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)","sponsor":"Astellas Pharma Global Development, Inc.","participation":[{"nct":"NCT07475806","source":"https://clinicaltrials.gov/study/NCT07475806","fetchedAt":"2026-10-07T16:55:46.774Z","studySha256":"345c711042aa51fbdadd707151df0e4b5e202c43bd79edde99fde9663dd84caa","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-24","leadSponsor":"Astellas Pharma Global Development, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":240,"enrolmentType":"ESTIMATED","siteCount":48,"recruitingSiteCount":48,"countries":["Australia","France","Germany","Japan","Poland","South Korea","Spain","United Kingdom","United States"]}],"started":"2026-03-12","startedType":"actual","enrolled":240,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07475806/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}